These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17196075)

  • 21. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma.
    Lipworth BJ; Sims EJ; Das SK; Morice AH; O'Connor BJ
    Ann Allergy Asthma Immunol; 2005 Sep; 95(3):283-90. PubMed ID: 16200820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer.
    Randell J; Saarinen A; Walamies M; Vahteristo M; Silvasti M; Lähelmä S
    Respir Med; 2005 Dec; 99(12):1485-93. PubMed ID: 16226024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
    Brusasco V; Canonica GW; Dal Negro R; Scano G; Paggiaro P; Fabbri LM; Barisione G; D'Amato G; Varoli G; Baroffio M; Milanese M; Mereu C; Crimi E
    J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peak inspiratory flow rate after methacholine challenge in asthmatic patients and its impact on the effect of formoterol via different inhalers.
    Haidl P; Schmidt F; Wiese C; Koehler D
    J Aerosol Med; 2006; 19(3):364-71. PubMed ID: 17034311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
    Asking L; Lundbäck H; Persson B
    J Aerosol Med; 2002; 15(4):435-6; author reply 436-8. PubMed ID: 12581510
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial.
    Bodzenta-Lukaszyk A; van Noord J; Schröder-Babo W; McAulay K; McIver T
    Curr Med Res Opin; 2013 May; 29(5):579-88. PubMed ID: 23368897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
    Miller CJ; Senn S; Mezzanotte WS
    Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation.
    Wauthoz N; Hennia I; Dejaeger B; Ecenarro S; Amighi K
    Int J Pharm; 2017 Sep; 530(1-2):415-429. PubMed ID: 28757256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma.
    Hermansen MN; Nielsen KG; Buchvald F; Jespersen JJ; Bengtsson T; Bisgaard H
    Chest; 2006 May; 129(5):1203-9. PubMed ID: 16685010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formoterol provides long-lasting protection against exercise-induced bronchospasm.
    Bronsky EA; Yegen U; Yeh CM; Larsen LV; Della Cioppa G
    Ann Allergy Asthma Immunol; 2002 Oct; 89(4):407-12. PubMed ID: 12392386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formoterol dry-powder inhalation--Novartis/SkyePharma: Foradil MDDPI, Foradil MDPI, Foradil SkyeHaler, formoterol fumarate dry-powder inhalation.
    Drugs R D; 2004; 5(3):162-3. PubMed ID: 15139778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
    Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
    Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.
    Otto-Knapp R; Conrad F; Hösch S; Metzenauer P; Maus J; Noga O; Petzold U; Kunkel G
    Pulm Pharmacol Ther; 2008; 21(1):47-53. PubMed ID: 17475527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Miflonide/Foradil via Aerolizer compared with other anti-inflammatory and anti-obstructive therapeutic regimens].
    Gessner C; Stenglein S; Bräutigam M; Müller A; Schauer J
    Pneumologie; 2003 Mar; 57(3):137-43. PubMed ID: 12632292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of respiratory spacer devices on aerodynamic particle size distribution and fine particle mass of beclomethasone from metered-dose inhalers.
    Feddah MR; Davies NM; Gipps EM; Brown KF
    J Aerosol Med; 2001; 14(4):477-85. PubMed ID: 11791688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.